Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...9899100101102103104105106107108...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Drug repurposing to overcome resistance to various therapies for colorectal cancer. (Pubmed Central) -  Aug 28, 2019   
    Here, we review both preclinical and clinical efficacy, as well as cellular mechanisms, of some extensively studied repurposed drugs, including non-steroidal anti-inflammatory drugs, statins, metformin, chloroquine, disulfiram, niclosamide, zoledronic acid and angiotensin receptor blockers. The three major treatment modalities in the management of colorectal cancer, namely classical cytotoxic chemotherapy, molecular targeted therapy and immunotherapy, are covered in this review.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Systematic Evaluation of Light-Activatable Biohybrids for Anti-Glioma Photodynamic Therapy. (Pubmed Central) -  Aug 24, 2019   
    ...The PSBMs include 16:0 lysophosphocholine-BPD (16:0 Lyso PC-BPD), distearoyl-phosphoethanolamine-polyethylene-glycol-BPD (DSPE-PEG-BPD), and anti-EGFR cetuximab-BPD (Cet-BPD)...Our results revealed the variable trafficking and end effects of PSBMs, providing valuable insights into methods of PSBM evaluation, as well as strategies to select PSBMs based on subcellular targets and cytotoxic mechanisms. We demonstrated that biologically informed combinations of PSBMs to target lysosomes and mitochondria, concurrently, may lead to enhanced therapeutic effects against gliomas.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, paclitaxel / Generic Mfg., Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal:  Systemic Therapies for Advanced Squamous Cell Anal Cancer. (Pubmed Central) -  Aug 23, 2019   
    Other cytotoxic agents, especially docetaxel and paclitaxel, have shown activity in both the chemotherapy-naive and chemo-refractory setting and are currently being investigated in clinical trials. Finally, further to the promising results of early clinical trials, immunotherapy with checkpoint inhibitors (i.e. nivolumab and pembrolizumab) is likely to become a standard second-line treatment option.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Differences in clinical features and oncologic outcomes between metastatic right and left colon cancer. (Pubmed Central) -  Aug 23, 2019   
    The outcomes of patients with LCC were better than those of patients with RCC in terms of OS, progression-free survival (PFS) and ORR after treatment with FOLFIRI + cetuximab in the CRYSTAL and CALGB 80405 trials...LCC and RCC exhibit distinctive clinical features and epidemiology. However, we must further investigate the impact of these distinctive features and how they influence the differential oncologic outcomes.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  A Case of Stage ⅣRectal Cancer with Dyskeratosis Congenita (Pubmed Central) -  Aug 16, 2019   
    A 27-year-old man was diagnosed with dyskeratosis congenita from DKC1 gene mutation at 9 years of age and had been followed-up regularly.An upper gastrointestinal endoscopy performed for vomiting revealed gastric varices.Further examination resulted in a diagnosis of Stage Ⅳrectal cancer with portal hypertension, splenomegaly, liver, and lung metastasis and he was referred to our department.A laparoscopic splenectomy was performed, followed by a laparoscopic low anterior resection for rectal cancer.Subsequently, resection of the pulmonary and liver metastasis was performed, resulting in macroscopic radical resection.However, 3 months after the hepatectomy, unresectable multiple lung metastasis was detected and he received 5 courses of chemotherapy with cetuximab.A grade 3 skin rash was observed and chemotherapy was discontinued. After 5 courses, he had pneumothorax and received drainage.He had sudden respiratory failure 2 days after pleural adhesion therapy of OK-432 was performed.He was diagnosed with interstitial pneumonia induced by OK-432 and steroid pulse therapy, which resulted in his death without improvement 21 days after admission.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, ALT-803 / Altor BioScience, NantKwest
    Journal:  An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck. (Pubmed Central) -  Aug 15, 2019   
    Administration of both cetuximab and ALT-803 to mice harboring Cal27 SCCHN tumors resulted in significantly decreased tumor volume when compared to controls and compared to single-agent treatment alone. Overall, the present data suggest that cetuximab treatment in combination with ALT-803 in patients with EGFR-positive SCCHN may result in significant NK cell activation and have important anti-tumor activity.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
    Biomarker, Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, FDG PET, Metastases:  Early Biomarker With 18F-FDG PET for Treatment Optimization of Anti-EGFR Therapy in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) -  Aug 15, 2019   
    P=N/A,  N=150, Recruiting, 
    Overall, the present data suggest that cetuximab treatment in combination with ALT-803 in patients with EGFR-positive SCCHN may result in significant NK cell activation and have important anti-tumor activity. Completed --> Recruiting | N=11 --> 150 | Trial completion date: Jul 2016 --> Dec 2020 | Trial primary completion date: Jan 2015 --> Dec 2020
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Topics related to neoadjuvant chemotherapy for resectable liver metastases from colorectal cancer. (Pubmed Central) -  Aug 9, 2019   
    In addition, no evidence directly addresses whether targeted agents such as cetuximab and bevacizumab should be offered with chemotherapy in the preoperative setting of resectable patients, despite that these aggressive strategies could result in high response rates. To offer the reader an insight into these complex and unresolved issues we will give an overview of three hot topics related to neoadjuvant chemotherapy for initially resectable CRLM.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    An Unusual Mimicker of Irritable Bowel Disease (Exhibit Halls 3 and 4 (Street Level)) -  Aug 8, 2019 - Abstract #ACG2019ACG_2637;    
    Introduction: Delayed anaphylactic reaction to red meat is a rare phenomenon that was first recognized during clinical trials for cetuximab...Improvement on a red meat restricted diet is ultimately diagnostic. As was seen in this case, improvement is often drastic and long lasting if red meat products are avoided.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases:  AGMT_HNO_PN: Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck (clinicaltrials.gov) -  Aug 7, 2019   
    P3,  N=8, Terminated, 
    Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020 N=154 --> 8 | Trial completion date: Sep 2021 --> Jul 2019 | Recruiting --> Terminated | Trial primary completion date: Sep 2021 --> Jul 2019; Study stopped due to low recruitment
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment open:  INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy (clinicaltrials.gov) -  Aug 6, 2019   
    P2,  N=67, Recruiting, 
    Trial completion date: Aug 2025 --> Feb 2026 | Trial primary completion date: Aug 2020 --> Feb 2021 Not yet recruiting --> Recruiting
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Rituxan (rituximab) / Roche, Biogen
    Clinical, Journal:  Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract: A case report. (Pubmed Central) -  Aug 2, 2019   
    The risk of a second primary tumor is increased among patients older than 70. Therefore, it is necessary to follow them using total body CT scan and endoscopic techniques of gastrointestinal and genitourinary tracts, not only for the evaluation of the neuroendocrine tumor but also for the higher risk to develop other neoplastic diseases.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. (Pubmed Central) -  Aug 2, 2019   
    Anti-epidermal growth factor receptor (anti-EGFR) agents panitumumab and cetuximab, in combination with chemotherapy, have also prolonged survival among KRAS and all RAS wild-type mCRC patients...Combinations of immunotherapies, RTKs, monoclonal antibodies, and cytotoxic drugs are being investigated to provide broad-spectrum protection against relapse by simultaneously targeting many cancer hallmarks. Lastly, human epidermal growth factor receptor 2 (HER2) therapy has shown promise for HER2-positive mCRC patients, though larger clinical trials are required to secure FDA approval.